Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP

Neurology

Volumn 81, Issue 22, 2013, Pages 1945-1952

  Hu, William T ^a,b,c   Watts, Kelly ^a,b   Grossman, Murray ^d   Glass, Jonathan ^a,b,c   Lah, James J ^a,b,c   Hales, Chadwick ^a,b,c   Shelnutt, Matthew ^a   Deerlin, Vivianna Van ^e   Trojanowski, John Q ^e   Levey, Allan I ^a,b,c  

^a Department of Neurology ^*  (India)

^b Center for Neurodegenerative Diseases Research   (India)

^c Alzheimer's Disease Research Center   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Ab42 5 b amyloid 1 42; AD 5 Alzheimer disease; ALS 5 amyotrophic lateral sclerosis; AUC 5 area under the curve; CI 5 confidence interval; FTD 5 frontotemporal degeneration; FTLD 5 frontotemporal lobar degeneration; FTLD Tau 5 frontotemporal lobar degeneration with Tau inclusions; FTLD TDP 5 frontotemporal lobar degeneration with TAR DNA binding protein 43 (TDP 43) inclusions; IL 5 interleukin; P Tau181 5 Tau phosphorylated at threonine 181; Penn 5 University of Pennsylvania; PN 5 peripheral neuropathy; PSP 5 progressive supranuclear palsy; ROC 5 receiver operating characteristic; T Tau 5 total Tau

Indexed keywords

BIOLOGICAL MARKER; FAS ANTIGEN; INTERLEUKIN 23; TAR DNA BINDING PROTEIN; TAU PROTEIN; THREONINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL ARTICLE; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FRONTOTEMPORAL DEMENTIA; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; MALE; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; TAUOPATHY; TDP 43 PROTEINOPATHY;

AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DNA-BINDING PROTEINS; FEMALE; FRONTOTEMPORAL LOBAR DEGENERATION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-23; MALE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEINS; SENSITIVITY AND SPECIFICITY; TAU PROTEINS; THREONINE;

EID: 84891938183     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000436625.63650.27     Document Type: Article

References (31)

1. Forman MS, Farmer J, Johnson JK, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol 2006;59:952-962.
2. Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006;66:41-48.
3. Hu WT, Chen-Plotkin A, Grossman M, et al. Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology 2010;75:2079-2086.
4. Hu WT, Chen-Plotkin A, Arnold SE, et al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol 2010;119:669-678.
5. O'Bryant SE. Using blood markers for Alzheimer disease in clinical practice? Neurology 2012;79:846-847.
6. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130-133.
7. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257-268.
8. Gass J, Cannon A, Mackenzie IR, et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet 2006;15:2988-3001.
9. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006;442: 916-919.
10. Baker M, Kwok JB, Kucera S, et al. Localization of frontotemporal dementia with parkinsonism in an Australian kindred to chromosome 17q21-22. Ann Neurol 1997;42:794-798.
11. Ingelsson M, Ramasamy K, Russ C, et al. Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. Acta Neuropathol 2007;114:471-479.
12. Grossman M. Primary progressive aphasia: clinicopathological correlations. Nat Rev Neurol 2010;6:88-97.
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
14. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-1554.
15. Murphy BM, Swarts S, Mueller BM, van der Geer P, Manning MC, Fitchmun MI. Protein instability following transport or storage on dry ice. Nat Methods 2013;10: 278-279.
16. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69:570-580.
17. Kos K, Harte AL, da Silva NF, et al. Adiponectin and resistin in human cerebrospinal fluid and expression of adiponectin receptors in the human hypothalamus. J Clin Endocrinol Metab 2007;92:1129-1136.
18. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65: 403-413.
19. Acevedo A, Krueger KR, Navarro E, et al. The Spanish translation and adaptation of the Uniform Data Set of the National Institute on Aging Alzheimer's Disease Centers. Alzheimer Dis Assoc Disord 2009;23:102-109.
20. Bian H, Van Swieten JC, Leight S, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 2008;70:1827-1835.
21. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456-2477.
22. Mattsson N, Andreasson U, Persson S, et al. CSF biomarker variability in the Alzheimer's Association Quality Control Program. Alzheimers Dement 2013;9:251-261.
23. Soares HD, Potter WZ, Pickering E, et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol 2012;69:1310-1317.
24. Hu WT, Holtzman DM, Fagan AM, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 2012;79:897-905.
25. Peskind ER, Li G, Shofer J, et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol 2006;63: 936-939.
26. Hong Z, ShiM, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010;133:713-726.
27. Boxer AL, Gold M, Huey E, et al. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement 2013;9:189-198.
28. Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat 2012;8:85-93.
29. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795-804.
30. Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011;26 (suppl 3):321-329.
31. Morris JC, Aisen PS, Bateman RJ, et al. Developing an international network for Alzheimer research: the Dominantly Inherited Alzheimer Network. Clin Invest 2012;2:975-984.